4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Invites Affected Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Invites Affected Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Urged To Take Part In The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Violating Securities Laws
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
